Global Alpha-1 Antitrypsin Drugs Market to Reach $4 Billion by 2030
The global market for Alpha-1 Antitrypsin Drugs estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$4 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2022-2030. Prolastin C, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Glassia segment is readjusted to a revised 10.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $582.9 Million, While China is Forecast to Grow at 9% CAGR
The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$582.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$679.8 Million by the year 2030 trailing a CAGR of 9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.Select Competitors (Total 43 Featured) -
- Abeona Therapeutics
- Alnylam Pharmaceuticals
- Applied Genetic Technologies Corp
- Arrowhead Research Corporation
- Baxalta
- Baxter
- CSL Behring
- Grifols
- Kamada
- Shire
- Takeda Pharmaceutical Company Limited
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abeona Therapeutics
- Alnylam Pharmaceuticals
- Applied Genetic Technologies Corp
- Arrowhead Research Corporation
- Baxalta
- Baxter
- CSL Behring
- Grifols
- Kamada
- Shire
- Takeda Pharmaceutical Company Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.9 Billion |
Forecasted Market Value ( USD | $ 4 Billion |
Compound Annual Growth Rate | 9.8% |
Regions Covered | Global |